Pathophysiological studies have shown that the alveolocapillary transfer of small solutes is much faster in healthy smokers than in non-smokers. The effects of smoking on the pulmonary absorption of inhaled terbutaline were examined in normal subjects. Nine 
The transfer of small water soluble molecules from the alveoli to the blood has been studied extensively during the last decade to assess the functional integrity of the alveolocapillary barrier.' The radiolabelled tracer molecule technetium-99m diethylenetriamine pentaacetic acid (99mTc DTPA) is administered in aerosol form and the radioactivity monitored over the chest, to provide a measure of the pulmonary clearance of the tracer-that is, its rate of absorption from the lung. Several groups have confirmed the findings of Jones et al2 that the pulmonary clearance of 9'9Tc DTPA is much faster in healthy smokers than in non-smoking control subjects. '5 The difference in absorption of inhaled 99mTc DTPA between smokers and nonsmokers reflects a difference in the functioning of the alveolocapillary barrier, and this may affect the absorption of inhaled drugs. Most selective beta agonists are water soluble and they are frequently given by inhalation so that a high tissue concentration can be achieved in the lung. Differences in the rate of absorption 225 between smokers and non-smokers may affect the time course of the therapeutic effect and may be clinically relevant. The purpose of this study was to examine the effect of smoking on the pulmonary absorption of inhaled terbutaline in normal subjects, and its relation to the pulmonary clearance of 99mTc DTPA.
Methods

SUBJECTS
We studied 22 healthy men, nine smokers and 13 non-smokers. None of the smokers had a history of chronic bronchitis. The physical characteristics of the two groups of subjects were similar ( All subjects were studied at the same time in the morning after a fast of about 10 hours. The smokers were asked not to smoke before the measurements on the study day. To avoid buccal or gastrointestinal absorption of terbutaline, each subject was given a suspension of 5 g ofcharcoal in 25 ml ofwater to drink during the two minutes before and after the inhalation of terbutaline. In addition, subjects swallowed 10 g ofcharcoal dispensed in 50 ml ofwater one and two hours after the inhalation of terbutaline. They were instructed to swirl the charcoal suspension around in the mouth before swallowing it. The administration of charcoal has been shown to be effective in inhibiting *the systemic absorption of terbutaline administered orally.9
The absorption of terbutaline from the airways was studied twice in each subject with two different modes of inhalation. The order of the modes of inhalation was randomised, and a washout period of one to four weeks was allowed to elapse between the two parts of the study. On one study day a solution of terbutaline sulphate (2-5 mg/ml) was nebulised with an UltraVent nebuliser and the subject inhaled the aerosol by quiet tidal breathing for three minutes. The duration of inhalation was chosen on the basis of preliminary experiments, so that the dose of terbutaline delivered to the lungs was similar to the dose in two inhalations of dry terbutaline sulphate powder (see below).
On the other study day the subject inhaled two doses ( Individual curves of plasma terbutaline concentration versus time were used to obtain the maximum plasma concentration (Cmax) and the time to maximum plasma concentration (tmax). The rate ofappearance of terbutaline in plasma (increase rate) was expressed as the slope of the straight line (best fit) through the origin, time points being used up to and including tmax. Unless otherwise stated, results are presented as means (with standard deviations in parentheses) in the smokers and non-smokers. For the two modes of administration, the variables Cmax, tmax, and rate of increase were analysed first by analysis of variance. We then calculated the mean value after each administration for each patient and compared the means between smokers and non-smokers, using a t test without the assumption of equal variances between the two groups. Corresponding 95% confidence limits were computed. The level of significance was setatp = 005.
Results
All subjects had normal spirometric values (table 1) .
The inhaled 99mTcDTPA showed a uniform distribution throughout the lungs in all subjects (fig 1) . Composite curves for the mean values for clearance of 99"Tc DTPA from the lungs in smokers and non-smokers are shown in figure 2. In the non-smokers the count rate over the lungs fell monoexponentially to 50% of the initial value after 71 minutes. The clearance curve from the smokers had a steep initial slope, so that 50% of the initial count rate was reached after 21 minutes.
Concentrations of terbutaline increased much faster in the smokers than in the nonsmokers after inhalation of nebulised ter- butaline or dry powder (fig 2) . The Cmax values were nearly twice as high in the smokers as in the non-smokers (table 2), the difference being (confidence interval (CI) 06-18&7) nmol/l; p < 0 05. The tmax in the smokers was about one third of that in the non-smokers, the difference being 32 (CI 19-46) minutes; p < 0 0005. The rate of increase in terbutaline plasma concentration was much higher in the smokers than in the non-smokers. The difference was 2-1 (CI 0-8-3 3) nmol/l a minute;
When the plasma terbutaline concentration curves were compared with respect to the mode of administration, very little difference was noted between inhalation of nebulised terbutaline and dry powder, either in smokers or in non-smokers (fig 1, table 2) .
Mean peak inspiratory flow during inhalation of dry terbutaline powder was 59 (range 46-70) 1/min in the smokers and 56 (range 44-70) 1/min in the non-smokers. The mean (SD) total amount of terbutaline recovered in the urine after powder inhalation was 535 (131) nmol in the smokers and 563 (167) nmol in the non-smokers.
Discussion
This study shows that the plasma concentration of terbutaline is substantially higher in smokers than in non-smokers during the first 30 minutes after its inhalation as a nebulised solution or as dry powder.
To ensure delivery of similar amounts of drug to all subjects, the inhalation procedure was standardised and monitored. We collected urine from the subjects after inhalation of dry terbutaline powder and found little difference in urinary excretion of terbutaline over 36 hours between smokers and non-smokers. This shows that the dose of drug delivered to the lungs was similar in the two groups of subjects.
Buccal and gastrointestinal absorption of terbutaline was inhibited by administering charcoal suspension to the subjects. Charcoal given in this manner has been shown to adsorb 97% of an oral dose of terbutaline.9 The large differences in Cmax and tmax after the inhalation indicate therefore that absorption of the inhaled drug from the lungs is much faster in smokers than in non-smokers. The smokers in this study were all free from respiratory symptoms and had normal spirometric values. The increased rate of terbutaline absorption is therefore most likely to be due to the effect of tobacco smoke on the physiological barrier functions in the lung.'
The differences in plasma concentration of terbutaline between smokers and non-smokers were seen with both modes of administration. Nebulised terbutaline when inhaled from an UltraVent nebuliser is deposited mainly in the peripheral airways (fig 1) , whereas terbutaline inhaled as dry powder is deposited more in central airways." Smoking therefore appears to affect the rate of terbutaline absorption from both central and peripheral airways.
The rationale for administering bronchodilators in aerosol form is to achieve a high local tissue concentration of the drug. The primary site of action of beta2 agonists is the bronchial smooth muscle. The drug penetrates the airway mucosa to reach the smooth muscle by diffusion or via the microcirculation. If the penetration of the mucosa is faster in smokers than in non-smokers, this could result in a Table 2 Mean (SD) maximum plasma concentration (Cmax), time to maximum plasma concentration (tmax), and calculated rate of increase in plasma concentration after inhalation of nebulised terbutaline solution or dry powder in smokers and nonsmokers, with 95% confidence limitsfor the differences between smokers and non-smokers
Non-smokers (n = 13) Confidence Nebulised Powder Nebulised Powder interval Cmax (nmol/1)
23 (16) 21 (9) 14 (4) 12 (4) 0-6-18.7 tmax (min)
17 (17) 17 (17) 50 (10) 50 (7) 19-46
Rate of increase (nmol/l/min) 2-6 (2 2) 2-2 (1-4) 0-3 (0-1) 0-6 (0 6) 08-3-3 faster onset of the therapeutic action in smokers.
The peak plasma concentration of terbutaline was much higher in smokers than in non-smokers. The relation between bronchodilatation and plasma concentration after inhalation has been studied in asthmatic subjects by van den Berg,'2 who found that a clearly detectable airway effect was associated with a peak plasma concentration of about 2 nmol/l. The therapeutic range of terbutaline plasma concentration for systemic treatment is 10-25 nmol/l.'3 The mean peak plasma concentration found in the non-smokers in this study was below the lower limit of the therapeutic range for systemic treatment, indicating that little therapeutic effect may be expected from recirculating drug. The plasma concentrations in the smokers during the first hour after inhalation of terbutaline were higher, and recirculating drug could therefore contribute to bronchodilatation in smokers. Systemic side effects after inhalation of terbutaline may also be more common in smoking than in nonsmoking subjects. Side effects were not assessed in this study.
The difference in the rate of increase in plasma concentration indicates that terbutaline is removed from the lungs at a higher rate in smokers than in non-smokers. To the extent that this reflects a difference in the rate ofdecline in terbutaline concentration at the site of action, it suggests that the duration of the therapeutic effect may be shorter in smoking than in non-smoking subjects. This could not be tested in this study of normal subjects.
The influence of lung disease on the pulmonary absorption of terbutaline is largely unknown, but some inference can may have a faster pulmonary absorption of the drug than normal subjects.
We have shown that the pulmonary absorption of terbutaline is much faster in smokers than in non-smokers. This may be relevant to its therapeutic effect, by giving a faster onset of action and a shorter duration of the therapeutic effect in smokers than in non-smokers. Further studies of the relation between smoking habits and the efficacy of aerosol bronchodilator treatment are warranted.
